Greatbatch says it might spin out its Algostim spinal cord stimulation subsidiary as a publicly traded company.
Profound Medical becomes a publicly traded with a reverse merger, raising a $24 million private placement to back clinical testing of its prostate cancer ablation device.
Profound Medical yesterday said it's slated to hit the public markets in Canada after a reverse merger, also revealing a $24 million private placement to fuel clinical trial work.
Hologic exceeds expectations again with its fiscal 2nd quarter, beating Wall Street's forecast and raising its outlook for the 2nd time this year.
Here's a look at some of the top legal news stories for medical device companies this week: Intarcia adds $225m for Type II diabetes trial; Gynesonics raises $3m for VizAblate fibroid device; Lombard Medical takes out $26m loan for Aorfix stent graft; Alliqua prices $30m offering; Contego Medical raises $6m for embolic filter tech
Doctors are still being paid by state Medicaid health insurance programs after being kicked out of another state's Medicaid system or the federal Medicare program.
(Reuters) — A doctor who took kickbacks from a Pennsylvania hospice involved in a multimillion-dollar fraud. An Ohio psychiatrist who billed for treating no-show patients. A Georgia optometrist who claimed he conducted 177 eye exams in 1 day.
Boston Scientific CEO Mike Mahoney says the company is aiming for double-digit earnings growth each year through 2019.
Vector is Children's Hospital Boston's blog about research and innovation in pediatric and adult medicine. We report and comment on medical innovations and advances – from bench to bedside – touching on scientific, business and policy issues. Our ranks include science writers, physicians, lab researchers, market analysts and others inside and outside the hospital.
